1. A family of novel TEAD palmitoylation site inhibitors with exceptional pre-clinical anti-neoplastic activity as a monotherapy and in combination with MAPK inhibitors. (October 2022) Authors: Muller, F.; Warshaviak, D.; Gyuris, J.; Nir, R.; Baloglu, E.; Shacham, S.; Morley, A.; Depinho, R. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗